title: Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients.
abstract: BACKGROUND
  Persistent hyperparathyroidism (HPT) is frequently observed in kidney transplant recipients. Hypophosphataemia is a common biochemical consequence of HPT. Theoretically, oral phosphorus administration may induce negative effects on the control of HPT, though this point has never been demonstrated in kidney-transplant recipients. This study was designed to evaluate the effects of oral phosphorus supplementation on the mineral metabolism of successful kidney transplant recipients.
  
  
  METHODS
  Thirty-two kidney transplant recipients with serum creatinine < 2 mg/dl and serum phosphate levels <3.5 mg/dl were included in the study. After a washout period in which oral phosphorus supplementation was discontinued, the following parameters were determined (F0 period): serum calcium, phosphate, alkaline phosphatase, uric acid, bicarbonate, PTH, 1,25-dihydroxyvitamin D3 (1,25 (OH)(2)D) and 25-hydroxyvitamin D3 (25OHD). Creatinine clearance, calcium, and phosphate excretion were determined from a 24-h urine sample. The same determinations were repeated (F1 period) after all patients received 1.5 g of oral phosphorus for 15 days. For data analysis, patients were divided into two subgroups (optimal and suboptimal) according to allograft function (Ccr>or < 70 ml/min/1.73 m2).
  
  
  RESULTS
  In the F0 period, only nine of 32 patients had PTH levels within the normal range (<65 pg/ml). The mean concentrations of PTH, 1,25(OH)(2)D and 25OHD were 132+/-97pg/ml, 40.5+16pg/ml and 12.5+/-8.2 ng/ml respectively. Phosphorus supplementation led to significant reductions in serum calcium and 1,25(OH)(2)D concentrations, as well as in urinary calcium excretion in the whole group. On the contrary, serum phosphate, PTH, and urinary phosphate excretion increased significantly. The percentage increase in PTH concentrations after phosphorus supplementation were similar in patients with optimal and suboptimal allograft function (33 vs 36%). The reduction of 1,25 (OH)(2)D concentrations after phosphorus supplementation was observed mainly in the subgroup with optimal allograft function (21% reduction with respect to baseline values), while the mean 1,25(OH)(2)D concentrations in patients with suboptimal allograft function scarcely changed (1.4% increase). Changes in 1,25(OH)(2)D concentrations after phosphorus supplementation, expressed as a percentage of the initial concentrations, correlated positively with the percentage changes in PTH concentrations for the whole group, as well as for each subgroup. The best determinants for the percentage and the absolute increase in PTH concentration after phosphorus supplementation was the final serum phosphate concentration (F=4.84, r=0.37, P=0.035) and the increase in serum phosphate (F=7.69, r=0.45, P= 0.009) respectively.
  
  
  CONCLUSIONS
  Oral phosphorus supplementation led to a significant increase in the PTH concentration of kidney transplant recipients. The mean 1,25(OH)(2)D concentration decreased mainly in recipients with optimal allograft function. The counterbalance effect of PTH on 1,25(OH)(2)D production may account for the relative preservation of 1,25(OH)2D levels in recipients with suboptimal allograft function.
authors.affiliation: S. Nefrología, Hospital Universitario Infanta Cristina, Badajoz, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Caravaca
authors.forename: M A
authors.initials: MA
authors.lastname: Fernández
authors.forename: R
authors.initials: R
authors.lastname: Ruiz-Calero
authors.forename: J
authors.initials: J
authors.lastname: Cubero
authors.forename: A
authors.initials: A
authors.lastname: Aparicio
authors.forename: F
authors.initials: F
authors.lastname: Jimenez
authors.forename: M C
authors.initials: MC
authors.lastname: García
mesh_terms: D000284:Administration, Oral; D002117:Calcitriol / Q000627:therapeutic use; D002118:Calcium / Q000097:blood / Q000652:urine; D002120:Calcium Channel Agonists / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016030:Kidney Transplantation / Q000502:physiology*; D008297:Male; D018977:Micronutrients; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood / Q000652:urine; D010758:Phosphorus / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D014131:Trace Elements / Q000378:metabolism*; D014807:Vitamin D / Q000097:blood
chemical_list: D002120:Calcium Channel Agonists; D018977:Micronutrients; D010281:Parathyroid Hormone; D010710:Phosphates; D014131:Trace Elements; D014807:Vitamin D; D010758:Phosphorus; D002117:Calcitriol; D002118:Calcium